+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Minimal Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region - Global Forecast to 2027

  • PDF Icon


  • 175 Pages
  • December 2022
  • Region: Global
  • Markets and Markets
  • ID: 5703174

The global minimal residual disease testing market is valued at an estimated USD 1.2 Billion in 2022 and is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0% during the forecast period. Market growth is driven by rise in the number of patients with cancer and hematological malignancies, growing awareness drives regarding cancer by government, and increasing collaborations and partnerships between companies.

The PCR segment accounted for the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period

The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). In 2021, the PCR segment accounted for the highest growth rate in the minimal residual disease testing market. Device being easy to use, easy accessibility  of assay kits, and a good sensitivity are the major factors contributing the large share of this segment.

Hematological Malignancies applications segment accounted for the highest CAGR

Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.

Asia Pacific: The fastest-growing region minimal residual disease testing market

The global minimal residual disease testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period. 

The Asia Pacific minimal residual disease testing market is estimated to grow at the highest CAGR during the forecast period, primarily due to improving healthcare infrastructure, the presence of a large pool of patient population, the rising focus of key players in the region, government efforts to increase awareness about the detection of diseases, continuously rising healthcare expenditures, an increasing number of hospitals & clinical diagnostic laboratories in India and China, and the strengthening research base for diagnostic procedures across India, China, and Japan.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35%
  • By Designation: C-level - 30%, D-level - 20%, and Others - 50%
  • By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, Latin America -9%, and the Middle East & Africa - 3%

Lists of Companies Profiled in the Report:

  • Labcorp Inc. (US)
  •  F. Hoffmann-La Roche Ltd. (Switzerland)
  • Guardant Health (US)
  • Sysmex Corporation (Japan)
  • NeoGenomics Laboratories, Inc. (US)
  • Adaptive Biotechnologies Corporation (US)
  • ArcherDX, Inc. (US)
  • Asuragen Inc. (US)
  • Arup Laboratories Inc. (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Cergentis B.V. (Netherlands)
  • Molecular MD (ICON plc) (Ireland)
  • Invivoscribe, Inc. (US)
  • Mission Bio, Inc. (US)
  • Natera, Inc. (US)
  •  Opko Health, Inc. (US)
  • Quest Diagnostics (US)
  • Genetron Health (China)

Research Coverage:

This report provides a detailed picture of the global minimal residual disease testing market. It aims at estimating the size and future growth potential of the market across different segments, such as technology, application, and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall minimal residual disease testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Table of Contents

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.4 Currency
1.5 Market Stakeholders
1.6 Summary of Changes

2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.2 Primary Data
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Analysis
2.5 Study Assumptions
2.6 Risk Assessment
2.7 Limitations
2.8 Growth Rate Assumptions

3 Executive Summary4 Premium Insights
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Restraints
5.2.3 Opportunities
5.2.4 Challenges
5.3 Pricing Analysis
5.3.1 Indicative Pricing Model Analysis
5.4 Case Study Analysis
5.5 Ranges/Scenarios
5.6 Value Chain Analysis
5.7 Supply Chain Analysis
5.8 Porter's Five Forces Analysis
5.9 Ecosystem Analysis of the Global Minimal Residual Disease Testing Market
5.10 PESTLE Analysis
5.11 Tariff & Regulatory Landscape
5.11.1 Regulatory Bodies, Government Agencies & Other Organizations
5.12 Patent Analysis
5.13 Trends/Disruptions Impacting Customers' Business
5.14 Key Conferences & Events in 2022-2023
5.15 Key Stakeholders & Buying Criteria
5.16 Technology Analysis
5.17 Trade Analysis

6 Minimal Residual Disease Testing Market, by Technology
6.1 Introduction
6.2 Flow Cytometry
6.3 Polymerase Chain Reaction
6.4 Next-Generation Sequencing
6.5 Other Technologies

7 Minimal Residual Disease Testing Market , by Application
7.1 Introduction
7.2 Hematological Malignancy
7.2.1 Leukemia Myeloid Leukemia Lymphoblastic Leukemia Other Leukemias
7.2.2 Lymphoma Non-Hodgkin's Lymphoma (Nhl) Hodgkin's Lymphoma
7.3 Solid Tumor
7.4 Other Applications

8 Minimal Residual Disease Testing Market , by End-User
8.1 Introduction
8.2 Hospitals and Specialty Clinics
8.3 Diagnostic Laboratories
8.4 Academic and Research Institutes
8.5 Other End-Users

9 Minimal Residual Disease Testing Market, by Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Roe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Roapac
9.5 Latin America
9.6 Middle East & Africa

10 Competitive Landscape
10.1 Introduction
10.2 Key Player Strategies/Right to Win
10.3 Market Share Analysis
10.4 Revenue Share Analysis
10.5 Company Evaluation Quadrant
10.5.1 Stars
10.5.2 Emerging Leaders
10.5.3 Pervasive Players
10.5.4 Participants
10.5.5 Competitive Benchmarking
10.6 Start-Up Evaluation Quadrant
10.6.1 Progressive Companies
10.6.2 Starting Blocks
10.6.3 Responsive Companies
10.6.4 Dynamic Companies
10.7 Competitive Scenario and Trends
10.7.1 Product Launches & Approvals
10.7.2 Deals
10.7.3 Other Developments
10.8 Product Footprint Analysis of Top Players
10.9 Geographic Footprint Analysis of Top Players

11 Company Profiles
11.1 Key Players
11.1.1 Adaptive Biotechnologies Corporation
11.1.2 Archerdx, Inc. (Invitae Corporation)
11.1.3 Asuragen
11.1.4 Arup Laboratories
11.1.5 Bio-Rad Laboratories, Inc.
11.1.6 Cergentis B.V.
11.1.7 F. Hoffmann- La Roche Ltd
11.1.8 Guardant Health
11.1.9 Icon plc
11.1.10 Invivoscribe, Inc.
11.1.11 Laboratory Corporation of America Holdings
11.1.12 Mission Bio, Inc.
11.1.13 Natera, Inc.
11.1.14 Neogenomics Laboratories, Inc.
11.1.15 Opko Health, Inc.
11.1.16 Quest Diagnostics Incorporated
11.1.17 Sysmex Corporation
11.1.18 Genetron Health

12 Appendix

Companies Mentioned

  •  Adaptive Biotechnologies Corporation
  •  Archerdx, Inc. (Invitae Corporation)
  •  Arup Laboratories
  •  Asuragen
  •  Bio-Rad Laboratories, Inc.
  •  Cergentis B.V.
  •  F. Hoffmann- La Roche Ltd
  •  Genetron Health
  •  Guardant Health
  •  Icon plc
  •  Invivoscribe, Inc.
  •  Laboratory Corporation of America Holdings
  •  Mission Bio, Inc.
  •  Natera, Inc.
  •  Neogenomics Laboratories, Inc.
  •  Opko Health, Inc.
  •  Quest Diagnostics Incorporated
  •  Sysmex Corporation



Table Information